cemiplimab,pembrolizumab
regeneron,sanofi,merck
['cemiplimab', 'kn-826']
cemiplimab increased os regardless of histology and pd-l1 expression as 2nd line treatment in r/m cervical cancer. seems a good alternative in pd-l1 negative pts. however, percentage of pd-l1 pts here was triple of that in kn-826. #esmo22, 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.